{"url":"https://lda.senate.gov/api/v1/filings/0884c19a-41f0-40ac-8440-d63eefec8a23/","filing_uuid":"0884c19a-41f0-40ac-8440-d63eefec8a23","filing_type":"1T","filing_type_display":"1st Quarter - Termination","filing_year":2010,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/0884c19a-41f0-40ac-8440-d63eefec8a23/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Gary Martin, CFO","dt_posted":"2010-04-16T10:51:28.033000-04:00","termination_date":"2010-01-15","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1101 PENNSYLVANIA AVE, NW","registrant_address_2":"SUITE 700","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72576,"url":"https://lda.senate.gov/api/v1/registrants/72576/","house_registrant_id":35932,"name":"FABIANI & COMPANY","description":"Global trade","address_1":"800 Maine Ave SW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MONICA CORTES","contact_telephone":"+1 202-767-7386","dt_updated":"2023-05-09T22:25:10.947000-04:00"},"client":{"id":166261,"url":"https://lda.senate.gov/api/v1/clients/166261/","client_id":1005418,"name":"CRESTONE, INC.","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":false,"state":"CO","state_display":"Colorado","country":"US","country_display":"United States of America","ppb_state":"CO","ppb_state_display":"Colorado","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-11-01"},"lobbying_activities":[{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Funding for novel antibiotics research and development","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45284,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"DUPREE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":139,"name":"Natl Institutes of Health (NIH)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Funding for novel antibiotics research and development","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45284,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"DUPREE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":139,"name":"Natl Institutes of Health (NIH)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}